Amgen announced new Repatha combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, an siRNA that reduces lipoprotein by more than 90%. Additional data from Amgen’s Center for Observational Research and Amgen funded investigator studies, including YELLOW-III from Mount Sinai will be presented at the American College of Cardiology’s 72nd Annual Scientific Session together with World Heart Federation’s World Congress of Cardiology in New Orleans, LA, March 4-6, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Horizon Therapeutics reports Q4 EPS $1.21, consensus $1.09
- Early notable gainers among liquid option names on February 17th
- Amgen price target lowered to $260 from $280 at Truist
- Amgen price target lowered to $270 from $300 at Argus
- Amgen’s Tezspire approved in U.S. for self-administration in severe asthma